These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38929666)

  • 41. Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?
    Dubrava AL; Kyaw PSP; Newman J; Pringle J; Westhuyzen J; La Hera Fuentes G; Shakespeare TP; Sakalkale R; Aherne NJ
    Breast Cancer (Dove Med Press); 2023; 15():359-371. PubMed ID: 37197610
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer.
    Kim EY; Lee KH; Yun JS; Park YL; Park CH; Do SI; Chae SW
    Int J Clin Exp Pathol; 2017; 10(7):7929-7939. PubMed ID: 31966643
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma.
    Kim HS; DO SI; Kim DH; Apple S
    Anticancer Res; 2020 Mar; 40(3):1487-1494. PubMed ID: 32132048
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
    Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
    Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinicopathological features and androgen receptor expression in triple negative breast cancer at Lagos, Nigeria.
    Haruna M; Daramola AO; Awolola NA; Badr NM; Banjo AAF; Shaaban A
    Ecancermedicalscience; 2022; 16():1452. PubMed ID: 36405944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression and Clinical Significance of Androgen Receptor in Triple-Negative Breast Cancer.
    Asano Y; Kashiwagi S; Goto W; Tanaka S; Morisaki T; Takashima T; Noda S; Onoda N; Ohsawa M; Hirakawa K; Ohira M
    Cancers (Basel); 2017 Jan; 9(1):. PubMed ID: 28067809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-Cell Immunoglobulin Mucin 3 Expression on Tumor Infiltrating Lymphocytes as a Positive Prognosticator in Triple-Negative Breast Cancer.
    Byun KD; Hwang HJ; Park KJ; Kim MC; Cho SH; Ju MH; Lee JH; Jeong JS
    J Breast Cancer; 2018 Dec; 21(4):406-414. PubMed ID: 30607162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients.
    Schmidt G; Guhl MM; Solomayer EF; Wagenpfeil G; Hammadeh ME; Juhasz-Boess I; Endrikat J; Kasoha M; Bohle RM
    Arch Gynecol Obstet; 2022 Nov; 306(5):1689-1695. PubMed ID: 35377046
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Overexpression of Programmed Death-Ligand 1 Receptor mRNA as an Independent Negative Prognostic Factor for Triple Negative Breast Cancer.
    Purwanto I; Heriyanto DS; Ghozali A; Widodo I; Dwiprahasto I; Aryandono T; Haryana SM
    World J Oncol; 2020 Oct; 11(5):216-222. PubMed ID: 33117465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive value of PD-L1 expression to the efficacy of immune checkpoint inhibitors in advanced triple-negative breast cancer: A systematic review and meta-analysis.
    Qi Y; Yan X; Wang C; Cao H; Liu G
    Front Pharmacol; 2022; 13():1004821. PubMed ID: 36532783
    [No Abstract]   [Full Text] [Related]  

  • 53. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients.
    AiErken N; Shi HJ; Zhou Y; Shao N; Zhang J; Shi Y; Yuan ZY; Lin Y
    Int J Biol Sci; 2017; 13(9):1172-1179. PubMed ID: 29104508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CD24 May Serve as an Immunotherapy Target in Triple-Negative Breast Cancer by Regulating the Expression of PD-L1.
    Zhu X; Yu J; Ai F; Wang Y; Lv W; Yu G; Cao X; Lin J
    Breast Cancer (Dove Med Press); 2023; 15():967-984. PubMed ID: 38164371
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
    Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
    Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group.
    Van Bockstal MR; Cooks M; Nederlof I; Brinkhuis M; Dutman A; Koopmans M; Kooreman L; van der Vegt B; Verhoog L; Vreuls C; Westenend P; Kok M; van Diest PJ; Nauwelaers I; Laudus N; Denkert C; Rimm D; Siziopikou KP; Ely S; Zardavas D; Roberts M; Floris G; Hartman J; Acs B; Peeters D; Bartlett JMS; Dequeker E; Salgado R; Giudici F; Michiels S; Horlings H; van Deurzen CHM
    Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer.
    Choi JE; Kang SH; Lee SJ; Bae YK
    Ann Surg Oncol; 2015 Jan; 22(1):82-9. PubMed ID: 25145503
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Is Programmed Death-Ligand 1 of Prognostic Significance in Triple-Negative Female Mammary Carcinoma?
    Sanad AM; Ibrahim WS; Ezzo IM; Sabry RM
    J Microsc Ultrastruct; 2024; 12(1):6-13. PubMed ID: 38633572
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer.
    Ahn SG; Kim SK; Shepherd JH; Cha YJ; Bae SJ; Kim C; Jeong J; Perou CM
    Breast Cancer Res Treat; 2021 Jul; 188(1):165-178. PubMed ID: 33770313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.